ASX ANNOUNCEMENT

ASX: CVB

26 November 2026

CurveBeam AI broadens US market access for HiRise™ with removal of distribution exclusivity

- **Conclusion of Stryker's US Foot & Ankle Division's Distribution Agreement removes exclusivity restrictions, expanding commercial opportunities for HiRise™**
- **CurveBeam AI expects no material reduction in HiRise™ placements and continues to progress its pipeline of more than 100 US prospects**
- **Greater commercial flexibility enables CurveBeam AI to pursue new orthopaedic partnerships, with knee and hip replacement priority growth opportunities**
- **The Australia and New Zealand referral agreement unaffected**
- **New Imaging as a Service model lowers barriers to adoption and has the potential to accelerate conversion of the existing sales pipeline**

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB) ("**CVB**", "**CurveBeam AI**" or the "**Company**"), a developer of point-of-care (PoC) specialised medical imaging (CT) equipment and AI enabled SaaS based clinical assessment solutions, has received formal notice from Stryker Foot & Ankle Division that its US Distribution Agreement will end on 1 January 2027.

The change to CurveBeam AI's US commercial arrangements gives the Company greater flexibility to sell HiRise™ directly and pursue new partnerships. CurveBeam AI will continue to work to convert its pipeline of several hundred US prospects into HiRise™ placements and expects no material reduction in placements because of the change. The Company's separate referral agreement with Stryker in Australia and New Zealand will continue.

Broader US market opportunity

The US agreement focused on Stryker's foot and ankle surgical planning workflows and generated fewer placements than CurveBeam AI expected. Its exclusivity limited the Company's ability to devise joint or bundled programs with other orthopaedic companies. The change broadens the scope for those partnerships, with knee and hip replacement a priority for HiRise™.

Frost & Sullivan's 2023 report identified 5,892 potential weight-bearing CT installation sites at US orthopaedic practices outside hospitals. An estimated 1.74 million total knee and hip replacements were performed in the US in 2023.

Most US primary knee and hip replacements are performed without robotic assistance. In 2024, the American Joint Replacement Registry reported robotic assistance in approximately 16% of primary total knee replacements and 7% of elective primary total hip replacements. HiRise™ supports imaging and planning for non-robotic procedures as well. Where foot and ankle scan volumes alone make a placement difficult to justify, adding knee and hip imaging allows more surgeons to use the same scanner, increasing potential utilisation and strengthening the business case for the whole practice.

Telephone: +61 3 9620 0250
Email: info@curvebeamai.com
Website: curvebeamai.com

Corporate Office
Level 10, 10 Queen Street
Melbourne, Victoria, 3000, Australia

Global Operations Headquarters
2800 Bronze Dr., Suite 110
Hatfield, PA 19440 USA

Robotic validation and industry partnerships
CurveBeam AI continues to evaluate HiRise™ imaging for use in surgical planning with Stryker's Mako robotic platform and other robotic platforms. The broader commercial approach allows the Company to pursue placements based on practices' existing imaging needs while progressing validation for additional robotic platforms and surgical planning workflows. This gives practices a path to adoption today and reduces the dependence of new placements on the timing of validation for any single platform.

Imaging as a Service model
CurveBeam AI's new Imaging as a Service model gives practices access to HiRise™ for a recurring service fee without an upfront equipment purchase. Depending on their procurement arrangements, practices may be able to fund the service through their operating budgets. The Company believes the addition of this option will help shorten sales cycles where capital approval has been a barrier, advance existing prospects and reach practices that may have deferred an equipment purchase.

CurveBeam AI CEO Greg Brown said: "The change removes a commercial hurdle for HiRise™. We can now build the case for a placement around the imaging needs of the whole practice. When foot and ankle, knee and hip surgeons can all use the same scanner, practices have more ways to generate the scan volumes that support a placement.

"Imaging as a Service makes that decision easier by removing the need to purchase the scanner upfront. Practices can move ahead based on the scans they need today while we continue validation work for additional robotic platforms. We believe broader market access and a lower upfront investment for practices will help us convert more of our US pipeline into HiRise™ placements."

Authorised by the Board

For further information go to https://curvebeamai.com

Forward-Looking Statements

This announcement contains certain forward-looking statements, including statements of intent, belief or current expectations with respect to the Company's business and operations, market conditions, results of operations and financial condition. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied in such statements.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, CVB undertakes no obligation to update or revise any forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which such statements are based.

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au